Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

By HospiMedica International staff writers
Posted on 12 May 2023

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. More...

However, this approach applies the same benchmark for all patients, failing to take into account variables like age, gender, and pre-existing health conditions which can influence troponin levels, thereby potentially compromising the accuracy of diagnosis and leading to disparities. Now, an artificial intelligence (AI)-based algorithm offers a speedy way to exclude heart attack possibilities in patients and assists clinicians in discerning if irregular troponin levels are the result of a heart attack or a different condition. The AI tool functions efficiently regardless of the patient's age, gender, or other health conditions, demonstrating its potential in mitigating diagnostic inaccuracies and disparities across various demographics.

The AI algorithm, termed CoDE-ACS, was created utilizing data from 10,038 patients in Scotland who presented to the hospital with suspected heart attack symptoms. The algorithm uses routinely gathered patient data, such as age, gender, ECG results, medical history, and troponin levels, to estimate the likelihood of a patient having experienced a heart attack. The outcome is a probability score ranging from 0 to 100 for each patient. CoDE-ACS could potentially enhance the efficiency and effectiveness of emergency care by swiftly identifying patients who can safely be discharged, while simultaneously flagging those who require further hospital testing.

Researchers from the University of Edinburgh (Scotland, UK) evaluated the efficacy of the algorithm, termed CoDE-ACS, on 10,286 patients across six nations. Their findings revealed that CoDE-ACS was able to exclude the possibility of heart attacks in over twice the number of patients compared to traditional testing methods, with a remarkable accuracy rate of 99.6%. This capability of ruling out heart attacks more swiftly could substantially decrease hospital admissions. In addition to promptly excluding heart attack possibilities, CoDE-ACS could also support clinicians in identifying patients whose abnormal troponin levels are attributable to a heart attack rather than a different medical condition.

“For patients with acute chest pain due to a heart attack, early diagnosis and treatment saves lives,” said Professor Nicholas Mills, BHF Professor of Cardiology at the Centre for Cardiovascular Science, University of Edinburgh, who led the research. “Unfortunately, many conditions cause these common symptoms, and the diagnosis is not always straight forward. Harnessing data and artificial intelligence to support clinical decisions has enormous potential to improve care for patients and efficiency in our busy Emergency Departments.”

Related Links:
University of Edinburgh 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.